United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. They have four approved products on the market today and they are not stopping there! From the United States to Europe to the Asia Pacific, they are proud of their multicultural business environment where employees can collaborate with people all over the world. As a group, they are relentless in their pursuit of “medicines for life”® and continue their research into treatments for pulmonary arterial hypertension, cancer, and some of the world’s most complicated viral illnesses.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Corsair Pharma, Inc. is a development stage biotechnology company. It focuses on the development of novel prodrugs of treprostinil to treat patients with pulmonary arterial hypertension using a once-daily transdermal patch. The company is headquartered in South San Francisco, CA.

SciPharm SARL focuses on developing pharmaceutical treatments against orphan diseases. It is also engaged in the development and distribution of precision ambulatory infusion pumps and a platform that connects medical devices to the cloud, which enables remote monitoring as well as distant programming of the devices. The company was founded in 2010 and is headquartered in Mertert, Luxembourg.

Chirogate International, Inc. is a Taiwanese private company located in Taoyuan that manufactures prostaglandin products.

Ascendis Pharma GmbH engages in research and development related to the administration of bioactive substances by cleavable linkers, as well as related activities. The company is headquartered in Heidelberg, Germany.

Pharmosa Biopharm, Inc. engages in research and development, research, and sale of innovative drugs and medical equipment. Its products include metered dose inhalers, soft mist inhalers, and liquid nebulizers. The company was founded in 1990 and is headquartered in Taipei, Taiwan.

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration.

Yonsung Fine Chemicals Co., Ltd. is a South Korean private company located in Hwaseong-si, also operating in Germany, that manufactures pharmaceuticals and chemical products. It was founded in 2001 by Won-Hun Ham and Chang-Yeong Oh. Chang-Yeong Oh has been the CEO since the inception date.

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

Jiangsu Zhongqiang Pharmaceutical Co., Ltd., established on 2019-02-28, Business scope includes pharmaceuticals,biopharmaceuticals,Pharmaceutical Intermediates,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),drug delivery equipment,Research and development of diagnostic instruments and equipment,Sales;medicine,biopharmaceuticals,Pharmaceutical Intermediates,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),laboratory consumables,Instrumentation,drug delivery equipment,Wholesale of diagnostic instruments and equipment,import and export,and provide supporting services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Emcure was born out of the vision to create a healthcare company that would address the vast healthcare needs. They commitment and drive have propelled our growth from a single manufacturing facility during the genesis, to a range of world class manufacturing facilities spread across API, formulations and biotechnology. Headquartered in Pune, India, Emcure is today a vertically integrated pharmaceutical company with infrastructure, skills and resources that are at par with the best in the world. Our strengths span research to the manufacturing of APIs, Formulations and Biotechnology. The Company has carved a niche for itself as a preferred outsourcing partner for some of the largest MNCs both in India and global markets.

Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The firm’s products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Westlake Village, California, the company was founded in February 1991. However, its present form is a result of a 2003 merger of three companies owned by Alfred E. Mann, Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing a allergy vaccine technology. MannKind Corporation was named after its founder, Alfred Mann. One of the former companies, Pharmaceutical Discovery, was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

Alphora is an FDA-approved contract research and manufacturing organization focused on process chemistry, cGMP scale up, and analytical method development for complex, small molecule APIs. Our services have supported numerous IND-enabling, clinical, and commercial API technology development programs over the past 13 years.

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Nanomi is a leader in the field of microsphere and nanoparticle manufacture and development of long-acting release medicines. The company earned this unique position by focusing not only on high-quality research, but also on the development of a pipeline of products based on its proprietary Microsieve technology, both in-house and in collaboration with partners. Nanomi has developed a cutting-edge technology - the Microsieve technology - for the development of long-acting release medicines, a technology that offers unprecedented drug development potential for the future.